Therapy News and Research

RSS

Crizotinib may be effective treatment option for NSCLC subtype

Phase I trial results show that the chemotherapy drug crizotinib may be fast-acting and produce long-lasting treatment responses in patients with anaplastic lymphoma receptor tyrosine kinase-positive non-small-cell lung cancer.

13 Sep 2012

FDG–PET/CT improves staging and modifies radiotherapy management

The addition of FDG–positron emission tomography/computed tomography revised radiotherapy decision-making and enhanced tumor staging capabilities in patients with non-small-cell lung cancer, research shows.

13 Sep 2012

Researchers hold new implications for pathogenesis of myotonic dystrophy

An important breakthrough could help in the fight against myotonic dystrophy. The discovery, recently published in the prestigious scientific journal Cell, results from an international collaboration between researchers at the IRCM, the Massachusetts Institute of Technology (MIT), the University of Southern California and Illumina.

13 Sep 2012

Four new studies on the treatment of early breast cancer

Four new studies on the treatment of early breast cancer, spanning from diagnosis through surgery, were released today in advance of the 2012 Breast Cancer Symposium.

13 Sep 2012

Changes in Troponin I protein can lead to cardiac muscle malfunction and precipitate heart failure

A new Johns Hopkins study has unraveled the changes in a key cardiac protein that can lead to heart muscle malfunction and precipitate heart failure.

13 Sep 2012

ACO 'predecessor' saved Medicare money, according to JAMA study

The study, found that the Medicare Physician Group Practice Demonstration resulted in health care savings.

13 Sep 2012

Biodel initiates BIOD-123 Phase 2 trial in Type 1 diabetes

Biodel Inc. today announced the initiation of a Phase 2 clinical trial of its proprietary recombinant insulin (RHI)-based ultra-rapid-acting mealtime insulin candidate, BIOD-123.

13 Sep 2012

Sanford-Burnham professor to develop personalized models of inherited heart conditions

The California Institute for Regenerative Medicine (CIRM) has awarded a $1.58 million grant to Huei-Sheng Vincent Chen, Ph.D., associate professor at Sanford-Burnham Medical Research Institute (Sanford-Burnham). Chen's proposal was one of 28 new projects funded as part of CIRM's Basic Biology IV awards program, which supports basic research aimed at increasing our understanding of stem cells and how to work with them.

13 Sep 2012

Predicting breast cancer drug response by 20/20 GeneSystems’ PredicTOR test

20/20 GeneSystems, Inc. will present results this week at the Breast Cancer Symposium 2012 (San Francisco) of a 45 patient study showing the usefulness of its PredicTOR test in predicting response of breast tumors to the drug Herceptin.

13 Sep 2012

Brigham Young University scientists discover cellular cause of birth defects

The cellular cause of birth defects like cleft palates, missing teeth and problems with fingers and toes has been a tricky puzzle for scientists. Now Professor Emily Bates and her biochemistry students at Brigham Young University have placed an important piece of the developmental puzzle. They studied an ion channel that regulates the electrical charge of a cell. In a new study published by the journal Development, they show that blocking this channel disrupts the work of a protein that is supposed to carry marching orders to the nucleus.

13 Sep 2012

Case Western Reserve researcher discovers new antivirulence drugs against MRSA and strep

Menachem Shoham, PhD, associate professor of biochemistry at Case Western Reserve University School of Medicine, has discovered novel antivirulence drugs that, without killing the bacteria, render Methicillin Resistant Staphylococcus Aureus (MRSA) and Streptococcus pyogenes, commonly referred to as strep, harmless by preventing the production of toxins that cause disease.

13 Sep 2012

Changes in physical characteristics of regulatory T cell can predict MDS progression risk

Researchers at Moffitt Cancer Center and colleagues have discovered that changes in the physical characteristics of the effector memory regulatory T cell can predict the progression risk of myelodysplastic syndromes (MDS) to acute myeloid leukemia. The finding could improve prognostication for patients with MDS and better inform therapeutic decision making.

13 Sep 2012

AtriCure receives FDA approval for surgical treatment of atrial fibrillation

AtriCure, Inc., the leader in surgical ablation for the treatment of Atrial Fibrillation, has announced FDA approval of the ABLATE Post Approval Study (PAS).

13 Sep 2012

Viewpoints: Questions Obama, Romney not likely to answer in debates; Disturbing news on tests for ovarian cancer

New evidence that women are more likely to be harmed than helped by screening tests for ovarian cancer is disturbing. The tests do nothing to prevent healthy women from dying from the usually fatal disease. Yet they often lead doctors to perform needless surgeries that cause serious complications in many patients.

13 Sep 2012

Genzyme receives FDA approval for AUBAGIO to treat relapsing forms of MS

Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has approved AUBAGIO (teriflunomide) as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS).

13 Sep 2012

Positive data from Tetraphase Pharmaceuticals’ eravacycline Phase 2 trial on cIAI

Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing novel antibiotics effective against antibiotic-resistant bacteria, presented new, positive Phase 2 clinical data on its lead drug candidate, eravacycline (TP-434), on September 11, 2012, at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.

13 Sep 2012

Combination chemotherapy confirmed viable for penile cancer

A combination of cisplatin and 5-fluorouracil is an effective and well-tolerated regimen for patients with squamous cell carcinoma of the penis, show study findings.

12 Sep 2012

Acupuncture therapy remains a prickly matter

Acupuncture may actually be effective for treating some types of chronic pain, a systematic review in the Archives of Internal Medicine shows.

12 Sep 2012

Transcept completes enrollment in TO-2061 Phase 2 trial for obsessive compulsive disorder

Transcept Pharmaceuticals, Inc. today announced that it has completed enrollment in its Phase 2 clinical trial evaluating TO-2061 added as adjunctive therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to first-line treatment with an approved OCD medication.

12 Sep 2012

Gene therapy regimen can safely restore immune systems to children with Bubble Boy disease

UCLA stem cell researchers have found that a gene therapy regimen can safely restore immune systems to children with so-called "Bubble Boy" disease, a life threatening condition that if left untreated can be fatal within one to two years.

12 Sep 2012

Therapy News and Research

Crizotinib may be effective treatment option for NSCLC subtype

FDG–PET/CT improves staging and modifies radiotherapy management

Researchers hold new implications for pathogenesis of myotonic dystrophy

Four new studies on the treatment of early breast cancer

Changes in Troponin I protein can lead to cardiac muscle malfunction and precipitate heart failure

ACO 'predecessor' saved Medicare money, according to JAMA study

Biodel initiates BIOD-123 Phase 2 trial in Type 1 diabetes

Sanford-Burnham professor to develop personalized models of inherited heart conditions

Predicting breast cancer drug response by 20/20 GeneSystems’ PredicTOR test

Brigham Young University scientists discover cellular cause of birth defects

Case Western Reserve researcher discovers new antivirulence drugs against MRSA and strep

Changes in physical characteristics of regulatory T cell can predict MDS progression risk

AtriCure receives FDA approval for surgical treatment of atrial fibrillation

Viewpoints: Questions Obama, Romney not likely to answer in debates; Disturbing news on tests for ovarian cancer

Genzyme receives FDA approval for AUBAGIO to treat relapsing forms of MS

Positive data from Tetraphase Pharmaceuticals’ eravacycline Phase 2 trial on cIAI

Combination chemotherapy confirmed viable for penile cancer

Acupuncture therapy remains a prickly matter

Transcept completes enrollment in TO-2061 Phase 2 trial for obsessive compulsive disorder

Gene therapy regimen can safely restore immune systems to children with Bubble Boy disease

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News